Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy
- 1 August 1994
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 74 (4), 363-368
- https://doi.org/10.1016/0002-9149(94)90404-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathyJournal of the American College of Cardiology, 1993
- Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomographyJournal of the American College of Cardiology, 1991
- Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy.Circulation, 1989
- Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography.Circulation, 1987
- Hypertrophic CardiomyopathyNew England Journal of Medicine, 1987
- Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures.Circulation, 1985
- Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries.Circulation, 1982
- Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.Circulation, 1979
- Quantitation in Positron Emission Computed TomographyJournal of Computer Assisted Tomography, 1979
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978